Rhenman & Partners Asset Management Ab Cti Biopharma Corp Transaction History

Rhenman & Partners Asset Management Ab

  • $1.01 Billion
  • Q2 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 14, 2021
SELL
$2.68 - $3.8 $804,000 - $1.14 Million
-300,000 Closed
0 $0
Q4 2020

Jan 19, 2021
BUY
$2.48 - $3.8 $744,000 - $1.14 Million
300,000 New
300,000 $966,000

About CTI BIOPHARMA CORP

CTIC Quotes by TradingView
  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track This Portfolio

Track Rhenman & Partners Asset Management Ab Portfolio

Follow Rhenman & Partners Asset Management Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email